Market Insights
Glaucoma is a chronic, degenerative disorder that damages the eye’s optic nerve and may result in vision loss and blindness. Factors such as the high prevalence of glaucoma, technological advancement in diagnostic techniques, and rising treatment awareness are driving the market growth of glaucoma therapeutics globally.
The report titled “Glaucoma Therapeutics Market: Growth, Future Prospects, and Competitive Analysis, 2017–2025” offers strategic insights into the overall glaucoma therapeutics market, along with the market size and estimates for the duration of 2015–2025. The research study covers an in-depth analysis of market segments based on drug class and different geographical regions.
The report also includes sections on the competitive profiling of the leading players in the global glaucoma therapeutics market, appealing investment propositions, and market positioning of key manufacturers to assist strategic decision-makers. Other in-depth analysis provided in the report includes:
Geographically, the global glaucoma therapeutics market is studied for the following regional markets:
- North America
- Europe
- Germany
- France
- UK.
- Italy
- Spain
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
- Latin America
- Brazil
- Mexico
- Rest of Latin America
- Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa
The market size and forecast for these regional and country-level markets are presented in this study for the period 2015–2025. Market growth rates for the forecast period 2017–2025 are also included in this report, considering 2016 as the base year.
Along with quantitative information, qualitative information sets and assessment tools are provided in this study for a better analysis of the overall market scenario and future prospects. Information such as market inclination insights and drivers, challenges, and opportunities assists the readers in understanding the ongoing trends in the global glaucoma therapeutics market.
Tools such as key player market positioning and appealing investment propositions provide readers with insights into the competitive landscape of the global glaucoma therapeutics market. This report concludes with a company profiles section that highlights major information about the key players engaged in the global glaucoma therapeutics market. In-depth competitive environment analysis and historical year (2015) market size data are also provided in the report.
Thus, the research study provides a holistic view of the global glaucoma therapeutics market, offering market size and estimates for the period from 2015 to 2025, keeping in mind the above-mentioned factors.
Based on drug class, the global glaucoma therapeutics market is segmented as follows:
- Prostaglandins Analogs
- Beta-blockers
- Alpha-adrenergic Agonists
- Carbonic anhydrase inhibitors
- Combinations Medication
Glaucoma is a chronic, degenerative condition that damages the eye’s optic nerve, resulting in vision loss and blindness. Factors such as an increase in the prevalence of eye disorders, significant unmet medical needs, and the rise in the incidence of age-related eye disorders are driving the market growth of glaucoma therapeutics globally. It is observed that in 2016, prostaglandin analogs were the largest revenue-generating segment because these are widely prescribed first-line treatments for glaucoma. Different studies indicated that fixed-dose combinations such as Dorzolamide and Timolol, Latanoprost and Timolol, and Brimonidine and Timolol are widely used on the market.
Patient adherence is higher for fixed-dose combinations as they reduce the risk of medication washout and also decrease the daily topical preservative load. It is observed that beta blockers are the second-largest revenue-generating segment; they may be used alone or combined with other medications. They lower the pressure inside the eye and are generally used to treat open-angle glaucoma. Some adverse effects associated with the use of alpha-adrenergic agonists include increases in heart rate and blood pressure, which negatively impact the growth of the therapeutic glaucoma market.
For the purpose of this study, the global glaucoma therapeutics market is categorized into three segments:
- North America
- Europe
- Asia Pacific
- Latin America (LATAM)
- Middle East and Africa (MEA)
In the base year 2016, North America dominated the glaucoma therapeutics market in terms of revenue, and it is anticipated that it will show steady growth during the forecast period of 2016–2024. Factors such as the rising geriatric population, the upsurge in funding by government agencies and private organizations in the healthcare system, the increasing incidence of eye disorders, and improved diagnostic techniques drive the growth of the glaucoma therapeutics market in North America. Europe is the second-largest revenue-generating regional market for glaucoma therapeutics. The U.K., Germany, and France are major revenue-contributing countries in Europe.
It is observed that the Middle East and Africa hold the smallest market share, and it is anticipated that they will show sluggish market growth during the forecast period. Comparatively lower costs of treatment medications hinder the market growth of glaucoma therapeutics in the Middle East and Africa. Currently, Asia Pacific is not a major revenue-generating segment. However, it is anticipated that it will experience significant growth during the forecast period. Factors such as an increasing population, continuous economic development, and developing healthcare infrastructure would contribute to market growth in Asia Pacific during the forecast period.
